TransMedics Group stock gained 1.47 percent as outlook holds

Published on 10/05/2026 at 10:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TransMedics Group stock traded at USD 79.80 on October 2, 2026, while its 2026 revenue outlook stayed at USD 737 million to USD 757 million. Q2 revenue reached USD 189.9 million.

TMDX, US89377M1099, Illustration mit AI erstellt.

TransMedics Group (ISIN US89377M1099) traded at USD 79.80 on Nasdaq at 4:00 p.m. ET on October 2, 2026, up 1.47 percent from the prior close. The company is maintaining a 2026 revenue outlook of USD 737 million to USD 757 million, giving the stock a fundamental growth anchor after its recent recovery from lower levels.

Revenue outlook stays intact

According to PR Newswire on September 10, 2026, TransMedics reiterated full-year 2026 revenue guidance of USD 737 million to USD 757 million. The range represents 22 percent to 25 percent year-over-year growth and excludes revenue from the company's strategic investment in PAD Aviation Service GmbH.

The guidance was reiterated alongside the appointment of Fernando Araujo as chief financial officer, effective September 21, 2026. The leadership change adds an execution angle to the outlook because TransMedics is expanding its organ logistics network and developing additional OCS applications.

Second-quarter revenue reaches USD 189.9 million

TransMedics generated USD 189.9 million in second-quarter 2026 revenue, according to Quartr. The figure gives the company a sizeable base for the full-year outlook, although the range still requires revenue growth across the second half of 2026.

Management has identified heart and lung expansion, the OCS Kidney program, European growth and the next OCS platform generation as longer-term drivers. The company also expects to revisit its financial outlook with its third-quarter 2026 results, according to PR Newswire.

Analysts see room above the stock

MarketBeat reported on October 5, 2026, that twelve ratings firms assigned TransMedics a consensus rating of Hold, with five Buy ratings, six Hold ratings and one Sell rating. The average 12-month price target was USD 121.10, which places the target 51.75 percent above the October 2 price of USD 79.80.

That spread reflects a divided setup: the revenue outlook remains firmly growth-oriented, while the market price is still well below its yearly peak. For investors, execution against the 22 percent to 25 percent growth range is the clearest numerical test for the next update.

Stock remains below its yearly high

TransMedics had a market capitalization of USD 2.8 billion and trading volume of 1,223,624 shares on October 2, 2026. The USD 79.80 price was 48.85 percent below the 52-week high of USD 156 and 32.78 percent above the 52-week low of USD 60.10.